Bariatric Times

FEB 2018

A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional

Issue link:

Contents of this Issue


Page 19 of 28

Review 19 Bariatric Times • February 2018 en-Y gastric bypass. Review Obes Surg. 2016;26:410–21. 15. Rubino F, Nathan DM, Eckel RH, et al. Delegates of the 2nd diabetes surgery summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77. 16. Chondronikola M, Harris LL, Klein S. Bariatric surgery and type 2 diabetes: are there weight loss- independent therapeutic effects of upper gastrointestinal bypass? J Intern Med. 2016;280:476–86. 17. Abbasi J. Unveiling the "magic" of diabetes remission after weight-loss surgery. JAMA. 2017;317:571–4. 18. Tadross JA, le Roux CW. The mechanisms of weight loss after bariatric surgery. Int J Obes. 2009;33Suppl 1:S28–32. 19. Vincent RP, Ashrafian H, le Roux CW. Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol. 2008;5:268–77. 20. Lim EL, Hollingsworth KG, Aribisala BS. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–14. 21. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of Euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52:1098– 103. 22. Wentworth JM, Playfair J, Laurie C, et al. Gastric band surgery leads to improved insulin secretion in overweight people with type 2 diabetes. Obes Surg. 2015;25:2400–7. 23. Pournaras DJ, Aasheim ET, Bueter M, et al. Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. Surg Obes Relat Dis. 2012;8:371–4. 24. Parikh M, Chung M, Sheth S, et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg. 2014;260:617–22. discussion 622–4 25. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5. 26. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93–102. 27. Panunzi S, De Gaetano A, Carnicelli A, Mingrone G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg. 2015;261:459–67. 28. Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39:166–74. 29. Yu H, Di J, Bao Y, Zhang P, Zhang L, Tu Y, et al. Visceral fat area as a new predictor of short-term diabetes remission after roux- en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. Surg Obes Relat Dis. 2015;11:6– 11. 30. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23. 31. Wentworth JM, Playfair J, Laurie C, Ritchie ME, Brown WA, Burton P, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2:545–52. 32. Ding SA, Simonson DC, Wewalka M, et al. Adjustable gastric band surgery or medical Management in Patients with Type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab. 2015;100:2546–56. 33. Schauer PR, Bhatt DL, Kirwan JP, et al. STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—3- year outcomes. N Engl J Med. 2014;370:2002–13. 34. Sjöström L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34. 35. Sjöström L, Lindroos AK, Peltonen M, et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93. 36. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122–31. 37. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695–704. 38. Schauer PR, Bhatt DL, Kirwan JP, et al. STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—5- year outcomes. N Engl J Med. 2017;376:641–51. 39. Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio- pancreatic diversion on diabetic complications: a 10-year follow- up. Diabetes Care. 2011;34:561– 7. 40. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311:2297–304. 41. Miras AD, Chuah LL, Khalil N, et al. Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case–control study. Diabetologia. 2015;58:1443–7. 42. Miras AD, Chuah LL, Lascaratos G, et al. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care. 2012;35:e81. 43. Gorman DM, le Roux CW, Docherty NG. The effect of bariatric surgery on diabetic retinopathy: good, bad, or both? Diabetes Metab J. 2016;40:354– 64. 44. Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–36. discussion 636–7 45. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65. 46. Fenske WK, Dubb S, Bueter M, et al. Effect of bariatric surgery- induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013;9:559–68. 47. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. JAMA. 2015;313:62–70. 48. Sjöström L, Narbro K, Sjöström CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52. 49. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61. 50. Sjöström L, Gummesson A, Sjöström CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–62. 51. Melissas J, Stavroulakis K, Tzikoulis V, et al. Sleeve gastrectomy vs. Roux-en-Y gastric bypass. Data from IFSO- European chapter Center of Excellence Program. Obes Surg. 2017;27:847–55. 52. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251:236–43. 53. Rohde U, Hedbäck N, Gluud LL, et al. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta- analysis. Diabetes Obes Metab. 2016;18:300–5. 54. Ponce J, Woodman G, Swain J, et al. REDUCE Pivotal Trial Investigators. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11:874–81. COPYRIGHT: © The Author(s). 2017. This article was originally published in BMC Endocrine Disorders. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// zero/1.0/) applies to the data made available in this article, unless otherwise stated. FUNDING: No funding was provided. DISCLOSURES: AK is an Associate Editor for BMC Endocrine Diseases. SL is a Section Editor for BMC Endocrine Diseases. AUTHOR AFFILIATION: Mr. Koliaki, Mr. Liatis, and Mr. Kokkinos are with the First Department of Propaedeutic Internal Medicine, Diabetes Centre, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens in Athens, Greece. Mr. le Roux is with the Diabetes Complications Research Centre, Conway Institute, University College Dublin in Dublin, Ireland and the Investigative Science department, Imperial College London in London, United Kingdom. ADDRESS FOR CORRESPONDENCE: Stavros Liatis; Email: sliatis@med.uoa. gr. BT

Articles in this issue

Links on this page

Archives of this issue

view archives of Bariatric Times - FEB 2018